Literature DB >> 18427144

Antioxidant gene therapy for cardiovascular disease: current status and future perspectives.

Anna-Liisa Levonen1, Elisa Vähäkangas, Jonna K Koponen, Seppo Ylä-Herttuala.   

Abstract

Excessive production of reactive oxygen species has been implicated to play an important role in a number of cardiovascular pathologies, including hypertension, atherosclerosis, myocardial infarction, ischemia/reperfusion injury, and restenosis after angioplasty or venous bypass grafting. The formation of reactive oxygen species is balanced out by antioxidant defenses, and augmenting this defense by antioxidant therapies could therefore provide a potential means to treat conditions in which the formation of reactive oxygen species exceeds the capability of natural protective mechanisms. In this review, we summarize the studies in which antioxidant gene therapy has been used successfully to treat cardiovascular diseases. We also discuss the current limitations of antioxidant gene therapy and envision future therapeutic targets and methodological approaches for an improved outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427144     DOI: 10.1161/CIRCULATIONAHA.107.718585

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

1.  Protective effect of propofol and its relation to postoperation recovery in children undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Wen-fang Xia; Yu Liu; Qing-shan Zhou; Qi-zhu Tang; Han-dong Zou
Journal:  Pediatr Cardiol       Date:  2011-06-03       Impact factor: 1.655

2.  Aging, metabolic syndrome and the heart.

Authors:  Guarner Veronica; Rubio-Ruiz Maria Esther
Journal:  Aging Dis       Date:  2012-03-13       Impact factor: 6.745

3.  Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.

Authors:  Noha M Shawky; Lakshman Segar
Journal:  Pharmacol Res       Date:  2017-02-14       Impact factor: 7.658

Review 4.  Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics.

Authors:  Frederick A Villamena; Amlan Das; Kevin M Nash
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

5.  Upregulated autophagy protects cardiomyocytes from oxidative stress-induced toxicity.

Authors:  Debapriya Dutta; Jinze Xu; Jae-Sung Kim; William A Dunn; Christiaan Leeuwenburgh
Journal:  Autophagy       Date:  2013-01-08       Impact factor: 16.016

Review 6.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

7.  Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis.

Authors:  Emanuela Branchetti; Rachana Sainger; Paolo Poggio; Juan B Grau; Jeffrey Patterson-Fortin; Joseph E Bavaria; Michael Chorny; Eric Lai; Robert C Gorman; Robert J Levy; Giovanni Ferrari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

Review 8.  Regulated production of free radicals by the mitochondrial electron transport chain: Cardiac ischemic preconditioning.

Authors:  Satoshi Matsuzaki; Pamela A Szweda; Luke I Szweda; Kenneth M Humphries
Journal:  Adv Drug Deliv Rev       Date:  2009-08-26       Impact factor: 15.470

9.  Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction.

Authors:  M Elena Padin-Iruegas; Yu Misao; Michael E Davis; Vincent F M Segers; Grazia Esposito; Tomotake Tokunou; Konrad Urbanek; Toru Hosoda; Marcello Rota; Piero Anversa; Annarosa Leri; Richard T Lee; Jan Kajstura
Journal:  Circulation       Date:  2009-08-24       Impact factor: 29.690

Review 10.  Small-diameter vascular tissue engineering.

Authors:  Dawit G Seifu; Agung Purnama; Kibret Mequanint; Diego Mantovani
Journal:  Nat Rev Cardiol       Date:  2013-05-21       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.